CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Baclofen Tablets18-04-2020
18-04-2020
Zydus Cadila gets USFDA nod to market generic cancer drug
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Erlotinib tablets in the strengths of 25 mg, 100 mg, and 150 mg, Zydus Cadila said in a statement.17-04-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Erlotinib Tablets17-04-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
Sale of 2% shares of Windlas Healthcare Private Limited, a subsidiary company.16-04-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for the Macitentan tablets15-04-2020
Cadila Healthcare shares rise 2% on USFDA nod to market diabetes drug
Zydus Cadila has received tentative approval from the USFDA to market Empagliflozin Tablets, in the strengths of 10 mg and 25 mg (US RLD: Jardiance Tablets), the company said in a filing to the exchanges13-04-2020
Zydus Cadila gets USFDA nod to market generic type 2 diabetes drug
The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Empagliflozin tablets, in the strengths of 10 mg and 25 mg, Zydus Cadila said in a statement.10-04-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receeives tentative approval from the USFDA for Empagliflozin Tablets10-04-2020
Drugmaker Zydus Cadila gets USFDA nod to market generic cancer drug
The company has received final approval from the USFDA to market its product which is a generic version of Gleevec tablets, Zydus Cadila said in a statement09-04-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA for Imatinib Mesylate Tablets09-04-2020